ArticleClinical drug investigation2011

Bevacizumab plus interferon-α versus sunitinib for first-line treatment of renal cell carcinoma in Italy: a cost-minimization analysis.

Roberto Ravasio et al.PubMed ↗Publisher ↗

No numbers read from the abstract.